ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0294

Prevalence and Severity of Anemia Between Non-Dialysis and Dialysis Outpatients Referred to Nephrology Consultation: Epidemiologic Data from 1568 Mexican Patients at a National Reference Hospital

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Perez-Navarro, L. Monserrat, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
  • Escorza Valdivia, Samantha, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
  • Benitez Renteria, Alberto Sigfrido, AstraZeneca, Ciudad de Mexico, Ciudad de Mexico, Mexico
  • Valdez-Ortiz, Rafael, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
Background

Anemia is a frequent complication in chronic kidney disease (CKD), and is frequently associated with symptoms such as physical disability, decreased neurocognitive function, and poor quality of life. Our objective is to know the prevalence and severity of anemia between stages of CKD in patients who attended a nephrology clinic for the first time.

Methods

Transversal, descriptive, observational study. Records of adult patients who attended an outpatient nephrology clinic in the period from February 2019 to February 2020 were included. Anemia staging was performed according to the world health organization. Descriptive statistics were performed, with a 95% CI and a p-value ≤0.05.

Results

1568 patient records were included. Mean age was 56.01 ± 16 years and 51% (804) were women. Distribution of patients by CKD stage: 9% stage 1, 11% stage 2, 12% stage 3a, 18% stage 3b, 23% stage 4, and 27% stage 5. 12% were undergoing renal replacement therapy. 53% of the population had anemia at the cut-off point of Hb<13 for men and <12 for women; stratification of anemia severity between stages of CKD is presented in figure 1. The main comorbidities and risk factors in the subjects with anemia were type 2 diabetes mellitus and hypertension (55%), proteinuria (38%), hypoalbuminemia (34%), hyperkalemia (37%) overweight or obesity (58%), hyperglycemia (45%) hypertriglyceridemia (35%) and hypercholesterolemia (31%).

Conclusion

In patients who attended for the first time an outpatient nephrology clinic, a high prevalence of anemia was found in CKD patients, being more frequent and more severe from stage 3b to stage 5. Identifying these findings will allow establishing public health policies and models of care for patients with CKD.

Funding

  • Commercial Support